MP35-11 LONG-TERM ONCOLOGICAL OUTCOMES OF DE NOVO BLADDER CANCER IN KIDNEY TRANSPLANT RECIPIENTS: RESULTS FROM A LARGE MULTICENTER INTERNATIONAL COHORT

Résumé fourni par la source

You have accessJournal of UrologyBladder Cancer: Epidemiology & Evaluation II (MP35)1 May 2024MP35-11 LONG-TERM ONCOLOGICAL OUTCOMES OF DE NOVO BLADDER CANCER IN KIDNEY TRANSPLANT RECIPIENTS: RESULTS FROM A LARGE MULTICENTER INTERNATIONAL COHORT Simone Livoti, Francesco Soria, Matteo Rosazza, Daniele Dutto, Fulvia Colucci, David D'Andrea, Ekaterina Laukhtina, Jeremy Teoh, Gautier Marcq, Denis Séguier, Renate Pichler, Felizian Lackner, Robin Martin, Thierry Roumeguere, Simone Albisinni, Benoit Mesnard, Wojciech Krajewski, Shahrokh Shariat, and Paolo Gontero Simone LivotiSimone Livoti , Francesco SoriaFrancesco Soria , Matteo RosazzaMatteo Rosazza , Daniele DuttoDaniele Dutto , Fulvia ColucciFulvia Colucci , David D'AndreaDavid D'Andrea , Ekaterina LaukhtinaEkaterina Laukhtina , Jeremy TeohJeremy Teoh , Gautier MarcqGautier Marcq , Denis SéguierDenis Séguier , Renate PichlerRenate Pichler , Felizian LacknerFelizian Lackner , Robin MartinRobin Martin , Thierry RoumeguereThierry Roumeguere , Simone AlbisinniSimone Albisinni , Benoit MesnardBenoit Mesnard , Wojciech KrajewskiWojciech Krajewski , Shahrokh ShariatShahrokh Shariat , and Paolo GonteroPaolo Gontero View All Author Informationhttps://doi.org/10.1097/01.JU.0001009372.61513.54.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Kidney transplant recipients face higher bladder cancer risk (BCa) than the general population. Moreover, these patients tend to manifest a more aggressive form of BCa, being often diagnosed at a more advanced stage and with higher-grade tumors than non-transplanted ones. Limited evidence exists on long-term outcomes, mostly from national registries or small retrospective series. This study aims to outline the characteristics and the oncological outcomes of de novo BCa in kidney transplant recipients in a large retrospective multicenter international cohort. METHODS: This was a multicenter retrospective collaboration involving 8 international referral centers. Kidney transplant recipients with de novo BCa diagnosed between 2000 and 2022 were included. The primary endpoint was to report tumor features at presentation and long-term oncological outcomes, focusing on recurrence-free (RFS), progression-free (PFS), cystectomy-free (CFS) and overall survival (OS). RESULTS: Overall, 89 patients were included. Median age at BCa diagnosis was 64 years (IQR 56-68), with a median time from kidney transplantation to BCa diagnosis of 98 months (IQR 50-161). At the time of presentation, the majority of patients were found to have muscle-invasive disease (61% vs 39%). Clinical tumor stage at diagnosis was cTa, cT1, cT2, cT3 and cT4 in 25 (29%), 9 (10%), 27 (31%), 25 (29%) and 1 (1%) patients, respectively. Overall, 33 (37%) patients underwent immediate radical cystectomy. Among the remaining 66 patients, 28 (42%) received intravesical adjuvant therapy (18 BCG and 10 chemotherapy), and subsequent disease recurrence and progression were observed in 21 (38%) and 5 (9%) of them, respectively. Ultimately, 13 (20%) of these patients required delayed radical cystectomy. The OS rates at 1, 3, and 5 years were 78%, 53%, and 47%, respectively. CONCLUSIONS: To our knowledge, this is largest series to date reporting long-term oncological outcomes in kidney transplant recipients who developed de novo BCa. Our findings confirm the aggressive nature of BCa in transplanted patients. Notably, a significant proportion of patients presented with muscle-invasive disease, a higher rate compared to non-transplanted BCa cases. Furthermore, our data highlight a substantial risk of disease progression in patients initially diagnosed with non-muscle invasive BCa. These results offer valuable insights for guiding the management of BCa in this unique patient population and underscore the importance of tailored strategies for optimal patient care. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e585 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Simone Livoti More articles by this author Francesco Soria More articles by this author Matteo Rosazza More articles by this author Daniele Dutto More articles by this author Fulvia Colucci More articles by this author David D'Andrea More articles by this author Ekaterina Laukhtina More articles by this author Jeremy Teoh More articles by this author Gautier Marcq More articles by this author Denis Séguier More articles by this author Renate Pichler More articles by this author Felizian Lackner More articles by this author Robin Martin More articles by this author Thierry Roumeguere More articles by this author Simone Albisinni More articles by this author Benoit Mesnard More articles by this author Wojciech Krajewski More articles by this author Shahrokh Shariat More articles by this author Paolo Gontero More articles by this author Expand All Advertisement PDF downloadLoading ...

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.